Breaking News
Investing Pro 0
Last Call for Cyber Monday! Save Now on Claim 60% OFF

Weekly biotech pulse: Big catalysts on tap for Sarepta, Roche, Eyenovia, and more

Published May 08, 2023 06:07AM ET Updated May 08, 2023 06:32AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.
 
SRPT
0.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
PLX
+2.80%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
RHHBY
+0.15%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
MCRB
-3.12%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
EYEN
+1.41%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Vlad Schepkov

Investing.com -- Here is your weekly Pro Recap preview of key biotech and FDA catalysts to look out for in the next week: PDUFA reviews for Eyenovia and Protalix, an earnings release and Phase 1 results for Seres Therapeutics, and an FDA vote for Sarepta Therapeutics and Roche.

InvestingPro users always get news like this in real time. Start your 7-day free trial to see for yourself.

Eyenovia set for a review of its pupil dilation treatment

On Monday, make sure to watch Eyenovia (NASDAQ:EYEN), which is set for PDUFA review of MydCombi - the company's drug candidate for treatment of pupil dilation (mydriasis).

Keep in mind the drug previously received a Complete Response Letter (CRL) from the FDA back in October 2021, although investors are definitely excited for a potential green light this time around: Shares are up nearly 170% year to date.

Wall Street analysts have a positive view of the stock, as well: 5 buy ratings, 1 hold, and 0 sells.

Protalix Biotherapeutics

Another day, another PDUFA. On the docket for Tuesday is a PDUFA review for Protalix Biotherapeutics' (NYSE:PLX) PRX-102 compound, its Fabry disease candidate - news that InvestingPro subscribers will get in rapid fire.

Protalix likewise got a CRL back in April 2021 and also appears to have regained some trust among investors ahead of the key decision: Shares have gained just shy of 140% since the start of the year.

The company has 3 buy ratings from analysts, 5 holds, and 0 sells ahead of the decision.

Seres Therapeutics

Seres Therapeutics (NASDAQ:MCRB) has scheduled its Q1 earnings release and conference call for Tuesday before the market opens.

The company is also set to announce initial Phase 1b Cohort 1 safety and pharmacology data for SER-155, its investigational drug for treatment of gastrointestinal infections, bacteremia, and GvHD (graft versus host disease).

The stock sports 12 Buys, 1 Hold, and 2 Sells from analysts.

Sarepta Therapeutics and Roche

On Friday, it'll be worth watching shares of Sarepta Therapeutics (NASDAQ:SRPT) and those of its partner - the OTC-listed ADRs of Roche (OTC:RHHBY), the Swiss-based pharmaceutical giant.

The companies are co-developing SRP-9001, a candidate to potentially treat Duchenne muscular dystrophy. The drug currently has an FDA Advisory Committee (AdCom) vote planned for Friday, with a PDUFA set some two and half weeks after that - on May 29.

Here's what a Morgan Stanley analyst had to say about the upcoming vote back in April:

We expect a supportive AdCom based on the evidence supporting the surrogate endpoint and continue to see the AdCom as an opportunity for mgt. to present their case publicly.

SRPT currently has 31 buys, 7 holds, and 1 sell across analysts.

Amid volatile markets and endless market-moving updates, seize on the right timing to maximize your profits: Always be the first to know with InvestingPro.

Start your free 7-day trial now.

InvestingPro | Be the First to Know

Weekly biotech pulse: Big catalysts on tap for Sarepta, Roche, Eyenovia, and more
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email